Erasca, Inc.

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (

In a series of moves that some analysts called unexpected, Erasca, Inc. unveiled the in-licensing of two preclinical RAS-targeted cancer compounds, outlined a planned $160m public offering and said

Recent private placements and follow-on financings show that despite public company valuations being down across the board during the past two years, it still is possible to drum up investor support f

A partnership between Alphabet’s Verily and OneOncology aims to improve the efficiency of cancer clinical trials, through the adoption of Verily’s SignalPath clinical trial management software acros